Results 91 to 100 of about 463,492 (156)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension

, 2017
Tian-Yu Lian, Xin Jiang, Zhi-Cheng Jing State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic ...
Lian TY, Jing ZC, Jiang X
core  

Probing Domain Interactions in Soluble Guanylate Cyclase

, 2016
Eukaryotic nitric oxide (NO) signaling involves modulation of cyclic GMP (cGMP) levels through activation of the soluble isoform of guanylate cyclase (sGC).
Emily R. Derbyshire (343638), Sarah Deng (2197573), Michael B. Winter (2197576), Michael A. Marletta (1858000), Thomas G. Spiro (1323057), Mohammed Ibrahim (1941412)   +5 more
core   +1 more source

Soluble Guanylate Cyclase Stimulators (Riociguat) in Pulmonary Hypertension: Data from Real-Life Clinical Practice in a 3-Year Follow-Up. [PDF]

Arq Bras Cardiol, 2022
Spilimbergo FB, Assmann TS, Bellon M, Hoscheidt LM, Caurio CFB, Puchalski M, Hochhegger B, Roncato G, Meyer GMB.   +8 more
europepmc   +1 more source

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial

Frontiers in Pharmacology
Heart failure is the most costly cardiovascular disorder. New treatments are urgently needed. This study aims to evaluate the safety, pharmacokinetics, and pharmacodynamic profile of HEC95468, a soluble guanylate cyclase (sGC) stimulator, in healthy ...
Yu-zhou Gui, Yu-zhou Gui, Wei Wang, Wei Wang, Qing-qing Wu, Qing-qing Wu, Qi-chen Ding, Qi-chen Ding, Hong-jie Qian, Hong-jie Qian, Qiu-bei Lu, Ying-jun Zhang, Yu-lei Zhuang, Li Deng, Ying-lin Zuo, Lin Luo, Jing-ying Jia, Jing-ying Jia   +17 more
doaj   +1 more source

Regulation of human erythrocyte Na+/H+ exchange by soluble and particulate guanylate cyclase

, 1996
Guanylate cyclase activity in human erythrocytes is investigated by evaluating the intracellular guanosine 3',5'-cyclic monophosphate (cGMP) content in the presence of various agents that exert specific effects on soluble or particulate guanylate cyclase.
P. Lijnen, V. Petrov
core   +1 more source

Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets

Medical Sciences
Cardiovascular diseases (CVDs) remain the leading global cause of morbidity and mortality, imposing an increasing clinical and socioeconomic burden. Despite significant therapeutic advances, optimal control of risk factors and long-term outcomes remain ...
Francesc Cabré, Marta Cascante
doaj   +1 more source

The discovery of small molecule modulators of soluble guanylate cyclase aided by surface plasmon resonance [PDF]

, 2014
Soluble guanylate cyclase is a multidimeric enzyme that regulates cardiovascular homeostasis and is the receptor for nitric oxide in the brain. The enzyme is the known target for a new agonist drug used for the treatment of pulmonary hypertension ...
Mota, F
core  

Human Soluble Guanylate Cyclase: Functional Expression, Purification and Structural Characterization

, 2001
Soluble guanylate cyclase is an enzyme that catalyzes formation of cGMP from GTP and is a member of the nucleotide cyclase family of enzymes. sGC is a receptor for endogenous and exogenous nitric oxide and is activated several-fold upon its binding ...
Young, Patricia, Uversky, Vladimir N., Gerber, Nancy Counts, Kosarikov, Dmitriy N.   +3 more
core   +1 more source

A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children

Children
This review delves into the most recent therapeutic approaches for pediatric chronic heart failure (HF) as proposed by the International Society for Heart and Lung Transplantation (ISHLT), which are not yet publicly available.
Bibhuti B. Das
doaj   +1 more source

Advances and unmet needs in pharmacologic therapy for pediatric heart failure: Insights from the 2025 International Society for Heart and Lung Transplantation Guidelines

Annals of Pediatric Cardiology
Backgrounds: Pediatric heart failure (PHF), most commonly resulting from cardiomyopathies, congenital heart disease, or acquired cardiac disorders, remains a major cause of childhood morbidity and mortality.
Bibhuti B. Das
doaj   +1 more source